Cormorant Asset Management, LP's Form 4/A amendment
AmendedErasca, Inc.ERAS · filed Dec 21, 2022
- Accession no.
- 0000929638-22-001904
- Filed
- Dec 21, 2022, 4:33 PM ET
- Trade date
- Dec 13, 2022
- Filing delay
- 8 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Dec 20, 2022
This filing lists 1 non-derivative transaction. Open-market purchases total $2.00M. It was filed 8 days after the trade.
This amendment replaces 0000929638-22-001901 (filed Dec 20, 2022).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cormorant Asset Management, LPCIK 0001583977 | Director |
| Chen BihuaCIK 0001599214 | Director |
| Cormorant Global Healthcare Master Fund, LPCIK 0001618442 | Director |
| Cormorant Private Healthcare Fund II, LPCIK 0001747677 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 13, 2022 | Common Stock | PPurchaseAcquired | +307,692 | $6.50 | +$1,999,998 | 10,813,246 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Ms. Chen disclaims beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Ms. Chen is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
- F2
Represents (i) 2,986,402 shares of Common Stock held by the Master Fund, (ii) 7,716,444 shares of Common Stock held by Fund II, and (iii) 110,400 shares of Common Stock held by the Account.
- F3
Shares reported herein as purchased on December 9, 2022 were purchased by the Master Fund.
- F4
Stock option grant for 166,666 shares, 41,667 shares of which become exercisable on 3/16/2022 and 124,999 shares of which become exercisable thereafter in equal monthly installments through 3/16/2025.
- F5
Stock options granted to Bihua Chen, in her capacity as a director of the Issuer.
Remarks
This amendment is being filed to clarify that the Form 4 filed by the Reporting Persons on December 20, 2022 was signed on such date and to correct a typographical error in the Date of Earliest Transaction reported in such Form 4.